Tdpoz5 Inhibitors
Tdpoz5 inhibitors comprise a class of chemical compounds engineered to specifically interact with the Tdpoz5 enzyme. These compounds are notable for their selective affinity towards the enzyme, aiming to alter its activity through a mechanism akin to a precise molecular interaction. The design of Tdpoz5 inhibitors is a complex task that requires a detailed understanding of the enzyme's structure, particularly the configuration of its active site. Crafting molecules that can effectively bind to this site without influencing other molecular targets is a challenge that necessitates advanced knowledge in various scientific domains.
The development and refinement of Tdpoz5 inhibitors involve a combination of computational and experimental strategies. Computational techniques such as molecular docking and simulations are employed to predict the manner in which these compounds will interface with the Tdpoz5 enzyme. These predictions serve as a blueprint for the chemical synthesis of the inhibitors, which are then subjected to a battery of biochemical assays. These assays are designed to quantify the interaction between the inhibitor and the enzyme, examining parameters such as binding affinity and the rate of interaction. Additionally, the physical and chemical properties of Tdpoz5 inhibitors, including their solubility, stability, and how they behave under various conditions, are meticulously assessed to understand the compound's characteristics outside of its primary interaction with the Tdpoz5 enzyme.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
PD98059 is a potent and selective inhibitor of MAPK/ERK kinase 1 (MEK1), which acts upstream of ERK in the MAPK signaling pathway. By inhibiting MEK1, PD98059 prevents the activation of ERK, which could indirectly lead to the downregulation of Tdpoz5 activity if Tdpoz5 is a downstream effector in this pathway. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 is a specific inhibitor of phosphoinositide 3-kinases (PI3Ks), which play a critical role in the AKT signaling pathway. Inhibition of PI3Ks leads to decreased AKT phosphorylation and activity, potentially reducing the expression or function of Tdpoz5 if it is regulated by AKT signaling. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB203580 is a selective inhibitor of p38 MAP kinase, involved in stress and inflammatory responses. Inhibition of p38 MAP kinase could affect Tdpoz5 if it is modulated by stress-activated signaling pathways that include p38 MAPK. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
U0126 is another MEK inhibitor that specifically inhibits MEK1/2, leading to a decrease in ERK phosphorylation. This compound would indirectly affect Tdpoz5 activity if Tdpoz5 functions downstream of the ERK pathway. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Wortmannin is a potent inhibitor of PI3Ks, acting similarly to LY294002. By inhibiting PI3K and subsequently AKT activation, Tdpoz5 function could be decreased if it is an AKT pathway target. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin is an inhibitor of the mammalian target of rapamycin (mTOR) pathway, which is involved in cell growth and proliferation. If Tdpoz5 is regulated by or involved in the mTOR pathway, rapamycin could indirectly inhibit its activity. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is a selective inhibitor of c-Jun N-terminal kinase (JNK), which is implicated in various cellular processes including apoptosis. If Tdpoz5 is associated with pathways involving JNK, its activity could be inhibited by SP600125. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $47.00 $145.00 | 51 | |
Dasatinib is a multi-targeted kinase inhibitor, but it is particularly known for its ability to inhibit Src family kinases. If Tdpoz5 is involved in signaling pathways that require Src kinase activity, dasatinib could result in reduced Tdpoz5 function. | ||||||
Gefitinib | 184475-35-2 | sc-202166 sc-202166A sc-202166B sc-202166C | 100 mg 250 mg 1 g 5 g | $62.00 $112.00 $214.00 $342.00 | 74 | |
Gefitinib selectively inhibits the epidermal growth factor receptor (EGFR) tyrosine kinase, which is involved in the proliferation and survival of cancer cells. If Tdpoz5 acts downstream of EGFR, its activity could be inhibited by gefitinib. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $56.00 $260.00 $416.00 | 129 | |
Sorafenib is a kinase inhibitor that targets multiple kinases including RAF, which is part of the MAPK pathway. Inhibition of RAF could lead to decreased Tdpoz5 activity if Tdpoz5 is involved in the RAF signaling axis. | ||||||